Company Overview - YingTai Medical (01501.HK) closed at HKD 24.750 on May 29, down 1.0% from the previous trading day, reaching a new low in nearly a year [1] - The company has a leading position in the domestic interventional cardiology device sector and is one of the few medical device manufacturers in China with complete industrial capabilities, including independent mold development, product research and development, equipment development, and sterilization [1][2] - YingTai Medical was established in 2006 and is listed on the main board of the Hong Kong Stock Exchange [1] Financial Performance - On the same day, the net capital outflow was HKD 6.93 million, with inflows of HKD 39,600 and outflows of HKD 108,910 [1] Product and Innovation - The company operates 16 subsidiaries focusing on various fields such as cardiology, peripheral, neurology, orthopedics, urology, ENT, exosome therapy, and ultrasound-focused non-invasive treatment [2] - As of June 30, 2024, the company holds 85 domestic registered products, 25 CE-certified products, and 20 FDA-certified products, along with 364 authorized patents and 199 pending patents [2] Recognition and Achievements - YingTai Medical has received multiple honors, including "National Specialized and New 'Little Giant'," "National Intellectual Property Advantage Enterprise," and "Shanghai Enterprise Technology Center" [2] - The company has been supported by over 70 government projects, including national and Shanghai innovation funds and major industrialization projects [2] Workforce and Future Vision - The company employs over 1,700 staff, with its main production base located in Jiading District, Shanghai [3] - YingTai Medical aims to become a globally recognized medical device group led by technological innovation, adhering to the development philosophy of "Innovation Serves Health, Quality Creates Excellence" [3]
瑛泰医疗盘中最低价触及24.750港元，创近一年新低